Wound Healing Metabolites to Heal Cancer and Unhealed Wounds

Cytotoxic agents were the choice of cancer establishments to combat cancer when President Nixon declared War on Cancer in 1971. After the failure to win the war on cancer during the 5 years of intensive presidential support, it was concluded that cytotoxic agents were unable to win the war on cancer. The emphasis of cancer research was then shifted from cytotoxic agents to DNA research, and gene and targeted therapies during the period of 1976 – 1995. Entire human genomes were sequenced which was a phenomenal achievement. The achievement, however, helped very little on cancer therapy. Studies of aberrant DNA methylations became a fashion, which, however, failed to grasp the critical issue of abnormal methylation enzymes to let the solution of cancer to slip away. Gene therapy was too difficult and too expensive to yield acceptable cancer drugs. Many excellent targeted drugs were discovered, which were good differentiation helper inducers to promote terminal differentiation of cancer cells. These excellent cancer drugs could not replace cytotoxic agents because they were unable to cause the tumor to disappear. These excellent targeted cancer drugs were primarily used for the therapy of hematological cancers. The emphasis was then shifted to anti-angiogenesis studies during 1995-2015, which did not produce good cancer drugs, and now to the immunotherapy, which has produced promising drugs for lung cancer. Immunotherapy has the potential to replace cytotoxic agents. Immunotherapy, however, appears to have the same problems as cytotoxic agents to cause damage to chemo-surveillance and to show ineffectiveness against cancer stem cells, which were primarily responsible for the failure of cytotoxic agents to win the war on cancer. Such deleterious effects can be remedied by the employment of cell differentiation agent formulations.